Abstract:

AIM:To study the therapeutic effect and the antimicrobial peptide LL-37 level of compound glycyrrhizin in patients with pigmented purpuric dermatosis（PPD）. METHODS:A total of 54 patients with PPD admitted to our hospital from April 2015 to April 2018 were enrolled in the study.They were randomly divided into observation group and control group,27 cases in each group,and 30 normal subjects were selected as a normal group.In the control group,oral methylprednisolone tablets and butyl flufenamate ointment were applied to the skin lesions;the observation group was given oral compound glycyrrhizin tablets;the normal group was not treated, and after 1 month，the evaluation was observed.The efficacy,adverse reaction rate and recurrence rate of the observation group and the control group were compared.The LL-37 level in serum of the three groups and the LL-37 level in skin lesions and the TNF-α,IL-6 and IL-17 levels in serum of the three groups were compared.RESULTS:Before treatment,there was no significant difference about the LL-37 level in serum and the LL-37 level in skin lesions and the TNF-α,IL-6 and IL-17 levels in serum between the observation group and the control group(P>0.05).After treatment，the LL-37 level in serum and the LL-37 level in skin lesions and the TNF-α,IL-6 and IL-17 levels in serum were decreased in both groups(P<0.05).The levels of TNF-α,IL-6 and IL-17 in observation group were significantly lower than those of the control group(P<0.05).Before and after treatment,serum LL-37 levels,skin LL-37 levels,and TNF-α,IL-6,and IL-17 levels were significantly higher in the observation group and the control group than those in the normal group (P<0.05).The effective rate of treatment in the observation group was 70.37%,which was significantly higher than that in the control group(51.85%) (P<0.05).The incidence of adverse reactions in the observation group was 18.52%,which was slightly lower than that in the control group(33.33%),but the difference was not statistically significant (P>0.05).The recurrence rate in the observation group was 11.11%,which was slightly lower than that in the control group 18.52%,but the difference was not Statistically significant (P>0.05).CONCLUSION:Compound glycyrrhizin can reduce the expression level of antibacterial peptide LL-37 in patients with pigmentary purpuric skin disease,reduce the inflammatory response,and the incidence of adverse reactions and recurrence rate is lower,the efficacy and safety are better,it is worthy of clinical promotion.

Key words: compound glycyrrhizin, pigmented purpuric skin disease, LL-37, clinical efficacy